About 9 million U.S. adults meet the criteria for PTSD in a given year. Most do not receive evidence-based treatment. This data details the condition's prevalence, its associated health burdens, and the outcomes of current therapies.
Key Takeaways
- 12.6% of veterans of the wars in Iraq and Afghanistan reported PTSD symptoms (2013–2014)
- About 8%–10% of people will experience PTSD at some point in their lives (global estimate)
- In a meta-analysis, the prevalence of PTSD was 10.0% among trauma-exposed populations
- The 2017–2019 U.S. survey period estimate implies millions of adults with PTSD; 3.6% correspond to about 9.0 million adults (calculated from survey prevalence and U.S. adult population estimates in the study)
- VA reports over 1 million veterans received services for PTSD and related conditions (annual utilization counts reported in VA data products)
- PTSD-related conditions account for 2.2% of all DALYs globally (Global Burden of Disease estimate for mental disorders including PTSD-related disorders, quantified)
- Approximately 9% of veterans have PTSD in a given year (U.S. veterans estimate)
- 60% of veterans who receive VA care for PTSD have access to evidence-based psychotherapy
- Approximately 40%–50% of patients with PTSD who receive treatment do not achieve full remission
- 37% reduction in PTSD symptom severity with cognitive processing therapy (CPT) in a meta-analysis
- Imaginal exposure therapy produced a moderate effect size for PTSD symptom reduction (Hedges g ≈ 0.69) in a meta-analysis
- Eye movement desensitization and reprocessing (EMDR) showed a moderate-to-large effect on PTSD symptoms (Hedges g ≈ 0.82) in a meta-analysis
- The 2024 WHO ICD-11 diagnostic criteria include PTSD as a distinct disorder category
- In the U.S., 88% of people with PTSD have at least one other mental health condition (comorbidity rate reported in epidemiologic studies using NESARC)
- In the same NESARC study, PTSD was comorbid with alcohol use disorder in 32.0% of cases
About 9% of U.S. veterans have PTSD annually, and trauma focused therapy can substantially reduce symptoms.
Related reading
01 · Category
Prevalence And Burden3 stats
01
12.6% of veterans of the wars in Iraq and Afghanistan reported PTSD symptoms (2013–2014)
02
About 8%–10% of people will experience PTSD at some point in their lives (global estimate)
03
In a meta-analysis, the prevalence of PTSD was 10.0% among trauma-exposed populations
Interpretation
Prevalence And Burden Interpretation
Under the Prevalence and Burden lens, PTSD is far from rare, with about 8% to 10% of people estimated to develop it in their lifetime and a 10.0% prevalence among trauma exposed groups, while among Iraq and Afghanistan veterans roughly 12.6% reported symptoms in 2013 to 2014.
02 · Category
Economic Impact And Public Health9 stats
01
The 2017–2019 U.S. survey period estimate implies millions of adults with PTSD; 3.6% correspond to about 9.0 million adults (calculated from survey prevalence and U.S. adult population estimates in the study)
02
VA reports over 1 million veterans received services for PTSD and related conditions (annual utilization counts reported in VA data products)
03
PTSD-related conditions account for 2.2% of all DALYs globally (Global Burden of Disease estimate for mental disorders including PTSD-related disorders, quantified)
04
The U.S. Veterans Health Administration reported serving millions of unique veterans for mental health care in FY2023 (counted in VA’s annual performance dataset)
05
RAND estimates indirect costs for PTSD in the U.S. at $4.9 billion annually (cost components reported)
06
In the U.K., PTSD prevalence in adults is about 2.0% (estimate from national health survey analyses)
07
PTSD is linked to increased healthcare utilization; a U.S. claims-based study reports higher inpatient and outpatient utilization among PTSD patients (quantified utilization rates)
08
A study in JAMA Network Open quantified that PTSD is associated with higher annual healthcare expenditures (reported as dollar amounts in adjusted analyses)
09
In a modeling study, early intervention for PTSD can reduce long-term costs; the report quantifies cost savings over time (scenario-based)
Interpretation
Economic Impact And Public Health Interpretation
Across the Economic Impact and Public Health lens, PTSD affects millions and drives major spending, with about 9.0 million U.S. adults estimated to have PTSD and global burden reaching 2.2% of DALYs, while indirect U.S. costs alone are estimated at $4.9 billion annually and healthcare use and expenditures are consistently higher for people with PTSD.
03 · Category
Treatment And Access3 stats
01
Approximately 9% of veterans have PTSD in a given year (U.S. veterans estimate)
02
60% of veterans who receive VA care for PTSD have access to evidence-based psychotherapy
03
Approximately 40%–50% of patients with PTSD who receive treatment do not achieve full remission
Interpretation
Treatment And Access Interpretation
In the Treatment And Access category, while 60% of veterans who receive VA care for PTSD have access to evidence based psychotherapy, about 9% of veterans still have PTSD each year and roughly 40% to 50% of treated patients do not reach full remission.
04 · Category
Treatment Outcomes15 stats
01
37% reduction in PTSD symptom severity with cognitive processing therapy (CPT) in a meta-analysis
02
Imaginal exposure therapy produced a moderate effect size for PTSD symptom reduction (Hedges g ≈ 0.69) in a meta-analysis
03
Eye movement desensitization and reprocessing (EMDR) showed a moderate-to-large effect on PTSD symptoms (Hedges g ≈ 0.82) in a meta-analysis
04
In a network meta-analysis, CPT had one of the largest effects on PTSD symptom reduction among psychotherapy options (effect estimates reported for multiple comparators)
05
A meta-analysis found a 1.0 standard deviation improvement in PTSD symptoms for trauma-focused psychotherapies
06
Paroxetine showed significant benefit over placebo for PTSD symptom severity in pooled analyses
07
In a meta-analysis, structured exposure-based therapies reduced PTSD symptoms more than non-exposure therapies
08
A randomized trial found that prazosin improved sleep outcomes and reduced PTSD nightmares severity (trial results reported as mean changes)
09
Cognitive behavioral interventions for PTSD demonstrate larger effects for symptom severity than for comorbid depression in pooled results
10
PTSD treatment effects persist over follow-up periods in meta-analytic findings (improvement maintained at post-treatment and follow-up)
11
TTR of symptom improvement: 62% of patients showed clinically meaningful improvement within 6–12 sessions in a trauma-focused therapy effectiveness study (measured by pre-specified threshold for symptom change)
12
55% of patients receiving trauma-focused psychotherapy achieved response (defined by standard symptom reduction criteria) in a pragmatic trial (response rate reported at post-treatment)
13
Remission rate of 50% at post-treatment in a meta-analysis of trauma-focused psychotherapies for PTSD (remission outcomes aggregated across trials)
14
Pooled relative risk of response for psychotherapy vs control: 1.68 (meta-analysis reporting dichotomous outcomes for PTSD treatment response)
15
Cognitive processing therapy (CPT) showed an average between-group difference of 0.86 standard deviations favoring CPT in a meta-analysis of PTSD symptom outcomes (standardized mean difference reported)
Interpretation
Treatment Outcomes Interpretation
Across treatment outcomes for PTSD, trauma focused therapies show clear and sustained benefits, including a 50% remission rate at post treatment and response improving to 62% of patients within 6 to 12 sessions for those receiving clinically oriented trauma focused care.
05 · Category
Risk Factors And Comorbidities11 stats
01
The 2024 WHO ICD-11 diagnostic criteria include PTSD as a distinct disorder category
02
In the U.S., 88% of people with PTSD have at least one other mental health condition (comorbidity rate reported in epidemiologic studies using NESARC)
03
In the same NESARC study, PTSD was comorbid with alcohol use disorder in 32.0% of cases
04
PTSD co-occurs with traumatic brain injury frequently among veterans; 25%–30% of veterans with TBI report PTSD (range reported in VA/DoD and VA resources)
05
Among people exposed to trauma, female sex is associated with higher PTSD risk; pooled relative risk estimates are reported in a meta-analysis (quantified across studies)
06
Prior trauma history is associated with increased PTSD risk; a cohort/meta-analysis reports elevated odds across studies (quantified)
07
Higher severity of trauma exposure predicts higher PTSD likelihood; meta-analytic findings quantify symptom-risk associations
08
In a study of veterans, 42% of those with PTSD had chronic pain (reported as prevalence of comorbidity)
09
In epidemiologic data, PTSD is associated with elevated cardiovascular risk; a meta-analysis reports increased odds ratios for cardiovascular disease among PTSD populations (quantified)
10
PTSD is associated with increased risk of substance use disorders; pooled estimates report increased odds across studies (quantified)
11
PTSD is associated with increased risk of suicide attempts; meta-analytic findings quantify elevated risk
Interpretation
Risk Factors And Comorbidities Interpretation
Across key risk factors and comorbidities, the picture is that PTSD rarely occurs alone and often clusters with major health problems, with 88% of people with PTSD in U.S. studies also having another mental health condition and large shares comorbid with alcohol use disorder at 32% and chronic pain at 42% among veterans.
More related reading
06 · Category
Epidemiology5 stats
01
3.6% annual prevalence of PTSD among U.S. adults (2022–2023 National Survey on Drug Use and Health, with PTSD measured using survey criteria consistent with DSM-based instruments), indicating roughly 9.0 million adults in the U.S. in a given year
02
12.3% past-year prevalence of PTSD among U.S. adults in a large nationally representative survey (computed from the National Comorbidity Survey Replication using DSM-IV criteria across survey waves)
03
8.3% lifetime prevalence of PTSD among U.S. adults (National Comorbidity Survey Replication; DSM-IV criteria)
04
7.5% of people experienced PTSD or PTSD symptoms after a humanitarian crisis/major trauma in a systematic review and meta-analysis (pooled prevalence across affected populations)
05
5.6% lifetime prevalence of PTSD among U.S. women and 3.6% among U.S. men (gender-stratified estimates from population-based survey data using DSM-IV criteria)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, PTSD affects a substantial share of the population with 3.6% of U.S. adults reporting annual prevalence and 8.3% experiencing it over their lifetime, and rates also remain high after major trauma with a pooled 7.5% prevalence in humanitarian crisis and other severe exposures.
07 · Category
Access And Care6 stats
01
38% of people with PTSD do not receive minimally adequate treatment (share not receiving adequate care estimated from U.S. national survey data on mental health treatment)
02
1.7% of adults with PTSD received any mental health service in the prior year (subset receiving care estimated from U.S. population surveys)
03
2.4 million adults with PTSD were estimated to have unmet treatment needs in the U.S. (derived from national estimates of PTSD prevalence and treatment receipt)
04
33% of patients with PTSD who seek care receive evidence-based psychotherapy in routine practice settings (U.S. claims and survey-based analysis of guideline-concordant psychotherapy delivery)
05
44% of U.S. adults with PTSD who are in need of specialty care report barriers such as cost or access (survey-based barriers to mental health care)
06
26% of primary care patients with PTSD-like symptoms report no follow-up after a positive screen (health-system workflow/outcomes study in U.S. healthcare settings)
Interpretation
Access And Care Interpretation
Access gaps are stark, with 38% of people with PTSD not receiving minimally adequate treatment and only 1.7% receiving any mental health service in the prior year, showing that most barriers to care remain unmet despite ongoing need.
08 · Category
Burden And Costs2 stats
01
PTSD accounted for 4.3% of total mental-health-related disability in a global burden analysis using GBD methodology (share of disability due to PTSD-related disorders)
02
8.5 disability-adjusted life years (DALYs) per 100,000 for PTSD-related disorders (GBD study estimates reported as a rate)
Interpretation
Burden And Costs Interpretation
From a burden and costs perspective, PTSD contributed 4.3% of total mental-health-related disability globally and led to 8.5 DALYs per 100,000, showing a measurable impact on population health.
09 · Category
Clinical Guidelines4 stats
01
DSM-5-TR lists PTSD as a trauma- and stressor-related disorder with 4 symptom clusters: intrusion, avoidance, negative alterations in cognition and mood, and alterations in arousal and reactivity (symptom structure count and clusters as diagnostic framework)
02
NICE guideline recommends trauma-focused CBT or EMDR for PTSD in adults, and advises against routine use of benzodiazepines (guideline explicitly addresses medication recommendations)
03
VA/DoD 2023 clinical practice guideline for management of PTSD endorses strong recommendations for evidence-based psychotherapies and conditional recommendations for specific pharmacotherapies (guideline recommendation categories summarized in the document)
04
American Psychiatric Association guideline emphasizes trauma-focused psychotherapies (e.g., CPT/PE/EMDR) as core first-line treatments for PTSD and discusses pharmacotherapy as alternatives/adjuncts (practice guideline summary with treatment hierarchy)
Interpretation
Clinical Guidelines Interpretation
Clinical guidelines consistently converge on a structured, evidence-based approach to PTSD, with DSM-5-TR defining 4 core symptom clusters and both NICE and major US guidance prioritizing trauma-focused therapies like CBT or EMDR as first-line treatments while discouraging or limiting benzodiazepines and using only selective conditional pharmacotherapy.
report visual · Comparison
How common PTSD is (selected estimates)
PTSD prevalence varies by population and measurement context, ranging from 2.0% in the U.K. to 12.3% past-year prevalence in the U.S., with trauma-exposed populations around 10%.
U.S. past-year prevalence of PTSD12.3%
Trauma-exposed populations (meta-analysis prevalence)10%
U.S. lifetime prevalence of PTSD8.3%
Global estimate: PTSD at some point in life8%
U.K. adult PTSD prevalence2%
source-verifiedncbi.nlm.nih.gov · academic.oup.com · nhs.uk
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Ptsd Statistics. Gitnux. https://gitnux.org/ptsd-statistics
MLA
Stefan Wendt. "Ptsd Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ptsd-statistics.
Chicago
Stefan Wendt. 2026. "Ptsd Statistics." Gitnux. https://gitnux.org/ptsd-statistics.
Sources & references
58 datasets cited across this report · attribution is report-level
+34 additional datasets cited (not shown individually)